Chromosomal Instability (CIN) Phenotype, CIN High or CIN Low, Predicts Survival for Colorectal Cancer

被引:87
作者
Watanabe, Toshiaki [1 ,2 ]
Kobunai, Takashi [2 ,5 ]
Yamamoto, Yoko [2 ]
Matsuda, Keiji [2 ]
Ishihara, Soichiro [2 ]
Nozawa, Keijiro [2 ]
Yamada, Hideki [2 ]
Hayama, Tamuro [2 ]
Inoue, Eisuke [4 ]
Tamura, Junko [2 ]
Iinuma, Hisae [2 ]
Akiyoshi, Takashi [3 ]
Muto, Tetsuichiro [3 ]
机构
[1] Univ Tokyo, Dept Surg Oncol, Bunkyo Ku, Tokyo 1138655, Japan
[2] Teikyo Univ, Sch Med, Tokyo 173, Japan
[3] Canc Inst Hosp, Tokyo, Japan
[4] Kitasao Univ, Tokyo, Japan
[5] Taiho Pharmaceut, Tokyo, Japan
关键词
LEVEL MICROSATELLITE INSTABILITY; GENE-EXPRESSION SIGNATURE; II COLON-CANCER; ADJUVANT CHEMOTHERAPY; STAGE-II; ALLELIC LOSS; FLUOROURACIL; BENEFIT; 18Q; CARCINOMAS;
D O I
10.1200/JCO.2011.38.6490
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose To examine whether chromosomal instability (CIN) phenotype, determined by the severity of CIN, can predict survival for stages II and III colorectal cancer (CRC). Patients and Methods We determined microsatellite instability (MSI) and loss of heterozygosity (LOH) status in 1,103 patients (training [n = 845] and validation [n = 258] sets with stages II and III CRC). The LOH ratio was defined as the frequency of LOH in chromosomes 2p, 5q, 17p, and 18q. According to the LOH ratio, non-MSI high tumors were classified as CIN high (LOH ratio >= 33%) or CIN low (LOH ratio < 33%). CIN-high tumors were subclassified as CIN high (mild type; LOH ratio < 75%) or CIN high (severe type; LOH ratio >= 75%). We used microarrays to identify a gene signature that could classify the CIN phenotype and evaluated its ability to predict prognosis. Results CIN high showed the worst survival (P < .001), whereas there was no significant difference between CIN low and MSI high. CIN high (severe type) showed poorer survival than CIN high (mild type; P < .001). Multivariate analysis revealed that CIN phenotype was an independent risk factor for disease-free and overall survival, respectively, in both the training (P = .001 and P = .0155) and validation sets (P = .001 and P = .0076). Microarray analysis also revealed that survival was significantly poorer in those with the CIN-high than in the CIN-low gene signature (P = .0203). In a validation of 290 independent CRCs (GSE14333), the CIN-high gene signature showed significantly poorer survival than the CIN-low signature (P = .0047). Conclusion The CIN phenotype is a predictive marker for survival and may be used to select high-risk patients with stages II and III CRC. J Clin Oncol 30:2256-2264. (c) 2012 by American Society of Clinical Oncology
引用
收藏
页码:2256 / 2264
页数:9
相关论文
共 30 条
[1]   Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial [J].
Andre, Thierry ;
Boni, Corrado ;
Navarro, Matilde ;
Tabernero, Josep ;
Hickish, Tamas ;
Topham, Clare ;
Bonetti, Andrea ;
Clingan, Philip ;
Bridgewater, John ;
Rivera, Fernando ;
de Gramont, Aimery .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) :3109-3116
[2]   DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study [J].
Barratt, PL ;
Seymour, MT ;
Stenning, SP ;
Georgiades, I ;
Walker, C ;
Birbeck, K ;
Quirke, P .
LANCET, 2002, 360 (9343) :1381-1391
[3]   American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer [J].
Benson, AB ;
Schrag, D ;
Somerfield, MR ;
Cohen, AM ;
Figueredo, AT ;
Flynn, PJ ;
Krzyzanowska, MK ;
Maroun, J ;
McAllister, P ;
Van Cutsem, E ;
Brouwers, M ;
Charette, M ;
Haller, DG .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3408-3419
[4]  
Boland CR, 1998, CANCER RES, V58, P5248
[5]   Prognostic significance of allelic loss at chromosome 18q21 for stage II colorectal cancer [J].
Carethers, JM ;
Hawn, MT ;
Greenson, JK ;
Hitchcock, CL ;
Boland, CR .
GASTROENTEROLOGY, 1998, 114 (06) :1188-1195
[6]  
Edge S.B., 2010, AJCC cancer staging manual, V649
[7]   Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer [J].
Elsaleh, H ;
Joseph, D ;
Grieu, F ;
Zeps, N ;
Spry, N ;
Iacopetta, B .
LANCET, 2000, 355 (9217) :1745-1750
[8]   A GENETIC MODEL FOR COLORECTAL TUMORIGENESIS [J].
FEARON, ER ;
VOGELSTEIN, B .
CELL, 1990, 61 (05) :759-767
[9]   Accumulated clonal genetic alterations in familial and sporadic colorectal carcinomas with widespread instability in microsatellite sequences [J].
Fujiwara, T ;
Stolker, JM ;
Watanabe, T ;
Rashid, A ;
Longo, P ;
Eshleman, JR ;
Booker, S ;
Lynch, HT ;
Jass, JR ;
Green, JS ;
Kim, H ;
Jen, J ;
Vogelstein, B ;
Hamilton, SR .
AMERICAN JOURNAL OF PATHOLOGY, 1998, 153 (04) :1063-1078
[10]   Defining 'chromosomal instability' [J].
Geigl, Jochen B. ;
Obenauf, Anna C. ;
Schwarzbraun, Thomas ;
Speicher, Michael R. .
TRENDS IN GENETICS, 2008, 24 (02) :64-69